IVIG Privigen denied as non-formulary by Humana?

Humana's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Privigen (IVIG) as Non-Formulary

Humana's formulary (drug list) organizes covered medications by tier and may include only selected IVIG products at preferred coverage levels. Privigen (immune globulin intravenous, human — 10%) may be denied as non-formulary if Humana's plan has designated a different IVIG product as the preferred formulary agent, or if IVIG products are covered only through a specialty pharmacy or medical-benefit channel that requires a separate authorization pathway. The denial does not mean Privigen is uncovered under all circumstances — it means additional steps are required.

## Why This Denial Is Appealable

Non-formulary denials are appealable through a formulary exception process, which is distinct from (but may run parallel to) the standard medical appeal. A formulary exception is warranted when: (a) the formulary alternative is medically contraindicated for the specific patient, (b) the patient has experienced an adverse reaction to the formulary alternative, or (c) the formulary alternative is clinically ineffective for the patient's condition based on a documented trial. For IVIG products, differences in formulation, excipients, osmolality, and stability profiles can be clinically meaningful — your prescribing physician can document why Privigen specifically is appropriate for you.

## Your Federal Appeal Rights

• Internal appeal / formulary exception: ACA §2719 and ERISA §503 require Humana to provide a full-and-fair review. Most plans have a specific formulary exception request form — submit it simultaneously with or before the standard appeal.
• External review: If the exception and internal appeal are both denied, an IRO may review whether Humana correctly applied its non-formulary criteria. The external-review window is typically around four months. Expedited review is available when delay would seriously jeopardize health.

## Concrete Appeal Steps and Timeline

1. Identify the formulary alternative: request from Humana the name of the preferred IVIG product it would cover in place of Privigen. 2. Have your prescribing physician document, in writing, the clinical reason Privigen is medically necessary over the preferred alternative — adverse reaction history, formulation-specific need, or documented inadequate response to the alternative. 3. Submit a formulary exception request and internal appeal simultaneously with supporting documentation. 4. Track the timeline: pre-service standard exceptions must be decided within 72 hours under CMS guidance for Medicare plans, or within the plan's stated timeframe for commercial plans. 5. If the exception is denied, escalate to external review immediately.

## Documentation to Gather

• Denial letter specifying the formulary tier and the preferred alternative Humana would cover
• Adverse reaction records for any alternative IVIG product already tried
• Clinical records documenting why Privigen specifically is appropriate (formulation rationale from prescriber)
• Diagnosis and severity records confirming the underlying condition
• Prescriber letter of medical necessity and formulary exception justification

## Criteria-Mapping Structure

Obtain Humana's formulary exception criteria from the plan documents or member portal. List each criterion for a non-formulary exception. For each one, document the specific clinical fact — with date and source — that satisfies it. When your prescriber states Privigen is medically necessary, ensure that statement directly tracks back to a criterion in Humana's own policy rather than standing as a general assertion.